Haleon plc (NYSE:HLN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Haleon plc (NYSE:HLN) has earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $10.95.

HLN has been the topic of a number of analyst reports. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday. UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday.

Haleon Stock Performance

HLN opened at $9.11 on Friday. The business’s 50-day simple moving average is $9.61 and its 200 day simple moving average is $9.67. Haleon has a 52-week low of $7.89 and a 52-week high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The firm has a market capitalization of $41.24 billion, a PE ratio of 26.79, a PEG ratio of 2.95 and a beta of 0.29.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Baker Tilly Wealth Management LLC grew its position in shares of Haleon by 13.6% in the fourth quarter. Baker Tilly Wealth Management LLC now owns 67,384 shares of the company’s stock valued at $643,000 after purchasing an additional 8,079 shares during the last quarter. Douglas Lane & Associates LLC boosted its stake in Haleon by 1.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock valued at $82,274,000 after purchasing an additional 161,865 shares during the period. GAMMA Investing LLC grew its holdings in Haleon by 41.3% in the 4th quarter. GAMMA Investing LLC now owns 21,258 shares of the company’s stock valued at $203,000 after buying an additional 6,215 shares in the last quarter. Versant Capital Management Inc increased its position in Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after buying an additional 1,026,939 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.